Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 8/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.34 |
| ▸ | FADS1 | O60427 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295993 | 0.74 | SMN1; SMN2 (0.37) | POLBMAPTALDH1A1LMNAKMT2A | |
| SCHEMBL4321203 | 0.70 | ITGB1 (0.60) | ITGB1ITGA4 | |
| SCHEMBL1322661 | 0.70 | SMN1; SMN2 (0.39) | ITGB1ITGA4POLBMAPTALDH1A1 | |
| SCHEMBL297623 | 0.66 | ALDH1A1 (0.58) | POLBHDAC3HDAC1HDAC2GAA | |
| SCHEMBL12123722 | 0.65 | ITGB1 (0.48) | ITGB1ITGA4 | |
| SCHEMBL297337 | 0.65 | ALDH1A1 (0.64) | GAAMAPTALDH1A1LMNAKMT2A | |
| SCHEMBL12123729 | 0.64 | ITGB1 (0.46) | ITGB1ITGA4 | |
| SCHEMBL3163947 | 0.63 | ITGB1 (0.41) | ITGB1ITGA4ALDH1A1LMNA | |
| SCHEMBL6641198 | 0.59 | ATM (0.44) | POLBGAAMAPTALDH1A1KMT2A | |
| SCHEMBL4315764 | 0.58 | ITGB1 (0.52) | ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546610-B2 | Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of the derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20110313154-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF THE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318688-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF DERIVATIVES | PAH, DDC, AADAT | ITGB1 4840/4885ITGA4 4848/4885FADS1 411/4885 |
| US-20110313154-A1 | METHOD FOR PREPARING PHENYLALANINE DERIVATIVES HAVING QUINAZOLINE-DIONE SKELETON AND INTERMEDIATES FOR USE IN THE PREPARATION OF THE DERIVATIVES | PAH, DDC, ASNS | ITGB1 4852/4885ITGA4 4857/4885FADS1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.